Improving cancer treatment by enhancing immune response against pancreatic tumors
A precision oncology approach to integrating of tumor microenvironment suppressive cell modulators to enhance antitumor immunity
This study is looking at new ways to help the immune system fight pancreatic cancer by using special vaccines and treatments, and it invites patients to join clinical trials to see if these approaches can make a difference.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11146708 on NIH RePORTER |
What this research studies
This research focuses on pancreatic ductal adenocarcinoma (PDA), a type of cancer that is difficult to treat due to its suppressive tumor environment. The team is investigating a combination of vaccines designed to activate the immune system, specifically targeting T cells to infiltrate and attack the tumor. By integrating these vaccines with immune checkpoint inhibitors, the research aims to overcome barriers that prevent effective anti-tumor responses. Patients may have the opportunity to participate in clinical trials that explore these innovative treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with metastatic pancreatic ductal adenocarcinoma who have previously undergone treatment.
Not a fit: Patients with early-stage pancreatic cancer or those who have not received prior treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, improving survival rates and quality of life for patients.
How similar studies have performed: Other research has shown promising results with similar immunotherapy approaches, indicating potential for success in this area.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Le, Dung T — Johns Hopkins University
- Study coordinator: Le, Dung T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.